At termination of the study, patients completed a global assessment scale.
At the termination of the study, at 18th week, the surplus rats were sacrificed by cervical decapitation.
Blood and urine biochemical parameters, amongst others, were measured at an interim time point after 4 weeks and at termination of the study.
Unfortunately, severe side effects occurred in two patients with this compound in the phase II trial, leading to termination of the study.
Histopathological changes were investigated with renal tissue of euthanized mice, when an end-point criterion was reached or after termination of the study in Week 34.
The randomization code did not leave the hospital during the study and was not available to the investigators until after termination of the study.
When HFOV failure was ascertained, CMV was removed leading to the termination of the study and an alternative method of oxygenation (prone positioning or ECMO) was initiated.
The intermediate analysis is defined as the treatment evaluation during an initial stage of the study and may lead to the termination of the study.
At termination of the study at 10 months, mice exposed in utero also had greater lung tumor multiplicity than mice exposed only during lactation.
At the termination of the study, the lungs were harvested, weighed, and evaluated for metastases.
This trend continued until the termination of the study at 4.5 months of age.
